Stocks To Buy Now Blog

All posts by Christopher

SPYR Inc. (SPYR) Is ‘One to Watch’

  • Applied Magix is currently shipping five products to customers
  • The company plans to add new products to its offerings in 2022
  • Applied Magix is positioned to take advantage of unmet demand for Apple-compatible smart home and connected car products
  • The global smart home market is forecast to hit more than $187 billion in revenue by 2025, marking a CAGR of 15.75 percent from 2021
  • The company operates in rapidly growing markets
  • Both SPYR and its Applied MagiX subsidiary have experienced management teams in place
SPYR (OTCQB: SPYR), dba SPYR Technologies, is a technology company which, through its Applied MagiX Inc. subsidiary, develops and resells Apple(R)-ecosystem-compatible products with an emphasis on the growing, multibillion-dollar Internet of Things (“IoT”) Smart Home and Connected Car markets. SPYR continues to identify and target acquisitions with an aim of growing its footprint in the industry and expanding the products it offers consumers, including companies developing artificial intelligence and smart-technology products. In 2020, SPYR acquired Applied MagiX Inc., a registered Apple developer and reseller of Apple ecosystem compatible products with an emphasis on the smart home market, as a wholly owned subsidiary. Applied MagiX operates in the IoT market and, more specifically, the segment of the market related to the development, manufacture and sale of devices and accessories specifically built on Apple’s HomeKit(R) framework. These products work within the Apple HomeKit ecosystem and are exclusive to the Apple market and its consumers. Initially, while working to develop, manufacture and sell its own line of branded products, Applied MagiX will be sourcing HomeKit products and accessories from worldwide manufacturers, vetting and selecting best-of-breed products, selling them directly to consumers and supporting them. The company focuses on Apple consumers – a target market with higher disposable income and a demonstrated willingness to pay a premium for quality products. On average, Apple product users spend roughly twice as much on technology as other smartphone users. Those who purchase smart home products spend more than $3,000 on average. By creating smart hardware and software solutions exclusively for Apple consumers, SPYR addresses a problem faced by that market – having few “smart” devices that integrate with Apple’s HomeKit, despite being the most affluent and loyal consumers of tech products. Products The company’s Applied MagiX subsidiary offers multiple product lines to its target markets. First, the subsidiary is a reseller of third-party manufactured Apple HomeKit and Apple CarPlay compatible products. HomeKit comes pre-installed on every new iPhone, while the CarPlay platform is licensed by all major auto manufacturers. Applied MagiX identifies white label products, applies the company’s branding, improves the software and sells these improved products to consumers. Finally, Applied MagiX is developing its own proprietary line of smart home and connected car products, including Apple-compatible home cameras, sensors and alarms, as well as additional Apple-compatible smart car products in the iOS ecosystem. Among the subsidiary’s products sold to consumers are:
  • The MagixDrive Wireless CarPlay adapter, which allows users to access CarPlay wirelessly using their iPhones
  • The HomeKit Secure Video Camera with iCloud Storage
  • The Multipurpose Sensor with Alarm
  • The Environment and Motion Sensor
  • The Window and Door Contact Sensor
Market Outlook According to Statista, the global smart home market is expected to generate revenue of more than $104 billion in 2021. The market is forecast to hit more than $187 billion in revenue by 2025, recording a CAGR of 15.75 percent. The number of active households in the worldwide smart home market is expected to reach nearly 500 million by 2025. Household penetration is just over 12 percent in 2021 and is projected to nearly double by 2025 to more than 22 percent. Allied Market Research valued the global connected car market at more than $63 billion in 2019 and projected a CAGR of 17.1 percent, which would push revenue to more than $225 billion by 2027. Allied identified rising consumer demand for connectivity solutions, surging need for constant connectivity, increasing dependency on technology and an upsurge in tech-savvy population as key factors driving the projected growth of the connected car market. Management Team James R. Thompson is the CEO, President and General Counsel of SPYR. Over the past 28 years, Mr. Thompson has deftly managed a colorful spectrum of legal clients and situations. In the process, he has helped many companies – both large and small – thrive. Now he welcomes the challenge to take the company and his career in an entirely new direction. A native of Philadelphia, he holds a J.D. from Rutgers University and a Bachelor of Science from the University of Denver. Jennifer Duettra is the Executive Vice President of SPYR. She brings a great deal of knowledge in mobile gaming and pop culture to the company. She is an attorney and was thrilled by the prospect to combine her law experience with a chance to be creative. She is a native of Colorado and received her Bachelor of Arts in Political Science and Speech Communication from Colorado State University. She holds a J.D. from Harvard University. Trang Nguyen is the CFO of SPYR. From 2019 to 2020, she served as the Financial Reporting Manager for Del Taco, where she was responsible for the preparation and filing of periodic financial reports with the U.S. Securities and Exchange Commission. From 2016 through 2019, Ms. Nguyen was Accounting Manager for Pinnacle Tax Accounting in Los Angeles, California. She was a part of Ernst & Young’s audit team in Los Angeles from 2006 to 2008, leading engagements on interim and year-end ad SOX 404 auditing procedures for major enterprise accounts. Ms. Nguyen holds a Bachelor of Art, Business Economics (Minor in Accounting) from the University of California, Los Angeles. She is a certified public accountant with an inactive license. Dr. Harald Zink is the CEO, Founder and Chief Product Architect of SPYR subsidiary Applied MagiX. Prior to founding Applied MagiX, he was Director of Technologies and later Vice President of Technologies at Sarkissian Productions in Los Angeles. He also served as Director of Technologies at SMZ Technologies and, for more than 17 years, as Macintosh Technology Consultant to The Walt Disney Studios in Burbank, California. He speaks five languages and holds degrees from the University of California, Riverside. Kelly Clark is the COO of Applied MagiX. Before joining the subsidiary, he worked as Vice President of Sales Operations at TruClear Global. Prior to that, Mr. Clark was Senior Director of Program Management at Pacific Group Ventures and Operations Manager at Barco. He has also held operations management positions at Deluxe Digital Studios and Sony Pictures Entertainment. Mr. Clark holds a bachelor’s degree in international business from the University of Southern California. For more information, visit the company’s website at www.Spyr.com. NOTE TO INVESTORS: The latest news and updates relating to SPYR are available in the company’s newsroom at https://ibn.fm/SPYR

Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) New Patent Application Offering Improved Delivery Control, Enhanced Shelf Stability, of Psilocin

  • The full patent application covers multiple families of psilocin analogs. Psilocin is the active metabolite of psilocybin
  • In addition to improving delivery control, the company’s dermal application route can potentially eliminate undesirable side effects such as nausea
  • Mydecine appoints Dr. Saeid Babaei, PhD, as an independent board member. The appointment can help advance the company’s NASDAQ listing efforts, bringing decades of experience in biotech development and licensing and strategic advancements
  • Company intends to uplist to NASDAQ in Q1 2022
Improving delivery control and shelf stabilization of psilocybin’s active metabolite psilocin, two critical aspects for use in medical settings, is the key goal of a new patent application filed by Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA), a biotech and digital technology company focused on transforming the treatment of mental health and addiction disorders. The full patent application Mydecine filed covers multiple families of psilocin analogs, according to a company press release. “The goal of creating these improved second-generation compounds is to enable safer, more effective treatments for patients along with improved management of dosage and drug behavior for clinicians,” Mydecine Chief Science Officer Rob Roscow said, talking about the patent application in the context of the company’s R&D pipeline of nature-sourced psychedelic-assisted therapeutics, therapy protocols, novel compounds and unique delivery systems. “We believe these improvements are necessary for psychedelic medicines to become an accepted and adopted form of treatment,” Roscow added. Mydecine’s patent offers solutions that primarily address controllability of delivery and stability, in view of increasing psilocin’s potential for medical use. More specifically, Mydecine’s dermal route for administration of psilocin can address controllability concerns resulting from variations in onset time for each patient when psilocybin is administered orally. The company’s permeation enhanced prodrug provides more control over delivery and can potentially eliminate side effects like nausea by bypassing the digestive system. The company’s patent filing also includes a family of stabilized psilocin analogs to optimize shelf stability, bringing Mydecine closer to a drug that meets regulatory requirements and providing access to a reliable and stable source of psilocin for physicians. This is the latest application in a series of patent filings for the company’s technology, as part of a sustained effort to build up and strengthen its intellectual property portfolio in its commitment to reimagine addiction and mental health treatment with more effective and safer solutions. In November 2021, Mydecine filed a technology patent covering the creation of formulations that use nanoemulsion technology to increase, improve and stabilize bioavailability of repeatable properties of ingredients from traditional medicine. And in September 2021, Mydecine filed a final patent application for one of its lead drug candidates, MYCO-003, a psilocybin formulation designed to enhance treatment of anxiety and post-traumatic stress disorder. To further advance its drug pipeline and compliance with NASDAQ requirements, the company appointed Dr. Saeid Babaei, PhD, as an independent board member to its board of directors. “We are pleased to welcome Dr. Babaei to the team as he brings decades of experience in biotechnology development, award-winning discoveries in gene therapy, and licensing and strategic advancements for the companies he has founded and accelerated,” Mydecine Chairman and CEO Josh Bartch said. Dr. Babaei has over 20 years of academic and corporate experience in bringing drug products from early development to commercialization. Dr. Babaei’s experience covers multiple novel and first-in-class products, as well as remarkable business foresight as he has closed more than 25 licensing and strategic alliance transactions and raised more than $50 million in equity and debt financing throughout his career. “As Mydecine continues to move our lead candidates down the pipeline, Dr. Babaei will play an integral role in advancing our novel psychedelic-based therapeutic candidates as well as meeting NASDAQ listing requirements,” Bartch added. Mydecine plans to uplist to NASDAQ in the first quarter of 2022. For more information, visit the company’s website at www.Mydecine.com. NOTE TO INVESTORS: The latest news and updates relating to MYCOF are available in the company’s newsroom at https://ibn.fm/MYCOF

FingerMotion Inc. (FNGR) Research Agreement with Munich Re Sets Stage for Predictive Insurance Analysis Growth

  • Rich communication services (“RCS”) provider and big data analysis solutions developer FingerMotion has announced an agreement with Munich Re to form a collaborative research alliance to benefit life and health insurance risk evaluation
  • FingerMotion focuses its SMS, MMS, and big data products on China’s huge high-end phone consumer market
  • The company’s most recent quarterly report noted a 25 percent YOY quarterly growth in revenues attributed to SMS and MMS services
  • The Munich Re agreement follows FingerMotion’s contract earlier this year with Pacific Life Reinsurance to provide big data analytical services for Pacific Life’s insurance operations in China
Communications and big data technology platform builder FingerMotion (OTCQX: FNGR) is continuing to build reinsurance industry opportunities for its Sapientus data analysis platform, announcing Dec. 6 that its 99 percent-owned subsidiary Shanghai JiuGe Information Technology Co., Ltd. inked a collaborative research alliance with global reinsurance powerhouse Munich Re to improve understanding of morbidity and behavioral patterns in China’s marketplace, focusing on life and health insurance. “Today’s news sets the stage for a longer-term strategic mission to reinvent the way we provide insurance to customers in the future and transform the overall industry,” FingerMotion CEO Martin Shen stated (https://ibn.fm/8QoGF). “All the vital elements are in place,” Shen added. “With our distribution platform that enables wide-scale marketing throughout China, a growing network of partners and ongoing accumulation of increasing data points and observations will further strengthen our analytic power and extend our reach, enabling us to aid in the industry’s effort to better stratify risks and contain moral hazard, ultimately augmenting the efficiency of the overall insurance system.” FingerMotion is a U.S.-based mobile tech services provider that is focused on China’s consumer phone market, building revenues primarily from short and multimedia messaging (SMS and MMS) services there. But the company’s Sapientus division has caught the attention of insurance industry players, most notably global insurer Pacific Life. Pacific Life’s Re-insurance division in China finalized an agreement with FingerMotion earlier this year to receive consumer risk data generated by FingerMotion for efficiently processing claims while screening for fraud and abuse. China’s insurance risk and credit risk evaluation infrastructure is still underdeveloped, creating a particular need in the country for solutions such as the information Sapientus offers to help companies analyze consumer behaviors and establish predictive algorithms. “This is the third consecutive quarter of Big Data revenues and we expect it to continue and eventually outpace our existing revenue streams,” Shen stated earlier this fall (https://ibn.fm/RwHGj). The quarterly financial report released in conjunction with Shen’s statement noted 25 percent year-over-year growth in revenues attributed to SMS and MMS services, and an overall quarterly revenue growth to $5.39 million. For more information, visit the company’s website at www.FingerMotion.com. NOTE TO INVESTORS: The latest news and updates relating to FNGR are available in the company’s newsroom at https://ibn.fm/FNGR

Flora Growth Corp. (NASDAQ: FLGC) Launches European and Mexican Exports of CBD Skincare Brands

  • Colombian cannabis cultivator and international wellness product builder Flora Growth Corp. is building a global pipeline for its wide array of branded CBD and medicinal cannabis products
  • The company recently announced that it has begun fulfilling the first orders for its Mind Naturals and Awe CBD skincare brands with exports to Spain and Mexico outlets this month
  • Flora Growth cultivates cannabis at its 100-hectare (247-acre) property in central Colombia
  • Flora also has a GMP certified 16,000-square-foot manufacturing facility in Bogota that produces nearly 200 products for the CBD derivatives and medical cannabis markets
Cannabis cultivator and worldwide cannabidiol (“CBD”) brand builder Flora Growth (NASDAQ: FLGC) continues to expand its consumer product goods and wellness lifestyle technology internationally, recently receiving its first orders for its Mind Naturals and Awe CBD skincare brands from outlets in Spain and Mexico. The company’s e-commerce agreements with SHOWFIELDS and GlossWire’s digital beauty marketplace in October paved the way for the two skincare brands to roll out in international markets. Fulfillment of these initial purchase orders from Amma Spain and Mexico’s Evergreen CBD is anticipated as the company’s product is exported this month. Mind Naturals markets to young, incoming consumers while Awe provides a customizable experience to the prestige market. “After months of preparation, our products meet all the needs of today’s consumers and we are ready for new international markets,” Flora Beauty General Manager Andrew Restrepo stated in announcing the product orders (https://ibn.fm/IfPIP). “Incorporating cutting edge formulations, rigorous safety standards and sustainable packaging, we are confident that our products are positioned to be among the best in the beauty industry and pleased that recent industry recognition supports this.” The announcement states Mind Naturals has garnered praise from industry marketing firms and that Spain is gaining a CBD hub reputation as a country poised to serve as the exporter for the industry’s products to surrounding countries. Flora Growth’s Flora Lab division serves as the company’s base for research, development and manufacturing of pharmaceuticals, cosmetics and nutraceuticals with 3 GMP certifications. Earlier this year, a major positive development in Colombia’s legal outlook on exporting dried cannabis flower and producing cannabis food and beverage products has made Flora Growths’ operational buildup pay off. Flora has now developed an international distribution pipeline for its GACP-certified flower produced at its Colombian facilities – where GACP is the precursor certification for the flower to be used to produce EU-GMP certified derivatives – that can be marketed to end users around the world. Flora also completed an investment program in European Union GMP partner Hoshi International Inc. in August that is expected to create a pathway for European distribution of Flora’s medical cannabis products (https://ibn.fm/xVfBa). Flora Growth President and CEO Luis Merchan will provide an update in a Dec. 14 webinar on the company’s performance for 2021 and comment on the company’s financial guidance for 2022 (https://ibn.fm/7GmNj). For more information, visit the company’s website at www.FloraGrowth.ca. NOTE TO INVESTORS: The latest news and updates relating to FLGC are available in the company’s newsroom at https://ibn.fm/FLGC

Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Set to Proceed with its Phase 2a Fibromyalgia Study Following FDA Confirmation

  • Tryp just announced FDA confirmation for its IND application filed in November 2021
  • The confirmation allows the company to proceed with its Phase 2a study on the effectiveness of psilocybin-assisted therapy among patients with fibromyalgia
  • This clinical study will be one of the first to evaluate synthetic psilocybin for fibromyalgia in a Phase 2 study
  • It is set to commence in 2022 and will involve 20 fibromyalgia patients
Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) just announced that it would be proceeding with its upcoming Phase 2a fibromyalgia study, following a confirmation from the U.S. Food and Drug Administration (“FDA”) (https://ibn.fm/C20cT). Tryp submitted an Investigational New Drug (“IND”) application in November 2021 for its lead drug candidate, TRP-8802, to investigate the safety and preliminary effectiveness of psilocybin-assisted therapy among patients living with fibromyalgia (https://ibn.fm/dVKmq). The Phase 2a study, conducted in collaboration with Kevin Boehnke, Ph.D. from the University of Michigan, is set to kick off in 2022. This study will enroll 20 fibromyalgia patients and include a variety of secondary and exploratory endpoints, considering the high prevalence of co-morbidities such as poor sleep quality, anxiety, depression, and other conditions that patients living with fibromyalgia deal with every day. “The upcoming Phase 2a study with the University of Michigan for fibromyalgia represents a significant milestone for Tryp’s clinical programs. We are eager to begin enrolling patients in the study next year considering the significant, unmet needs of fibromyalgia patients,” noted Greg McKee, the Chairman and Chief Executive Officer (“CEO”) of Tryp Therapeutics. This clinical study will be among the first evaluations of synthetic psilocybin for fibromyalgia in a Phase 2 study. It is projected that the administration of psilocybin will increase neuroplasticity and address disrupted neural connections associated with nociplastic pain indications. Most importantly, this study will work towards shaking up the clinical thinking on how to deal with such neurological conditions while laying down the foundation for Tryp’s further studies using their novel, trademarked drug candidates. For more information, visit the company’s website at www.TrypTherapeutics.com. NOTE TO INVESTORS: The latest news and updates relating to TRYPF are available in the company’s newsroom at https://ibn.fm/TRYPF

Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) to Fund, Support First-Ever Psychedelic Treatment Clinic at Manhattan Hospital

  • Company receives grant to fund clinic for marginalized, underserved NYC communities
  • New clinic will offer psychedelic treatment with no out-of-pocket cost for individuals unable to afford the service
  • Program’s clinicians will receive specialized training
Cybin (NEO: CYBN) (NYSE American: CYBN), a biopharmaceutical company focused on progressing psychedelics to therapeutics, is marking key milestones in its mission to revolutionize mental healthcare. The company recently received a grant for the first-ever psychedelic treatment clinic at Lenox Hill Hospital (https://ibn.fm/zyerA). Part of Northwell Health, the largest healthcare system in New York State, Lenox Hill Hospital serves marginalized and underserved communities on the Upper East Side of Manhattan, New York. The hospital is working to become one of the first hospital-based clinical sites to offer psychedelic medicine in the United States. “It’s time for psychedelic medicine to climb down from the ivory tower and into the community,” said Cybin chief clinical officer Dr. Alex Belser. “We are honored to support this program at Lenox Hill Hospital to start a low-cost/no-cost psychedelic clinic for marginalized and underserved communities in New York.” One of Northwell Health’s flagship hospitals, Lenox Hill Hospital is a 450-bed, acute-care facility on Manhattan’s Upper East Side. The clinical program at the hospital’s Outpatient Center for Mental Health is dedicated to addressing health inequities by prioritizing care for marginalized and underserved populations. The new psychedelic treatment clinic, funded and supported in part by Cybin, will offer treatment with no out-of-pocket cost for individuals who would otherwise be unable to afford the service; the clinic will also offer psychedelic treatments to frontline healthcare workers who are having difficulty dealing with COVID-19. In addition, the program’s clinicians will receive specialized training in MDMA-, ketamine- and tryptamine-assisted psychotherapy, as well as in EMBARK, a transdiagnostic psychedelic psychotherapy model. Created by Belser and his colleague Bill Brennan, EMBARK offers a wide range of flexibility. The model can be adapted to address a range of clinical indications and populations. “Lenox Hill Hospital is excited by the potential of these modalities for the treatment of previously intractable conditions such as severe depression, chronic PTSD and OCD,” said David Roane, MD, chair of psychiatry at Lenox Hill Hospital. “With this grant from Cybin, Lenox Hill Hospital aims to become one of the first hospital-based clinical sites offering psychedelic medicine in the country and is dedicated to addressing health inequities by prioritizing care for marginalized and underserved populations. In particular, people of color are greatly underrepresented in psychedelic research studies, and our team is committed to inclusive recruitment of patients.” Cybin is a leading ethical biopharmaceutical company and is working with a network of world-class partners and internationally recognized scientists to create safe and effective therapeutics to address a multitude of mental health issues. The company operates in the United States, the United Kingdom and Ireland. The company is focused on progressing psychedelics to therapeutics by engineering proprietary drug-discovery platforms, innovative drug-delivery systems, novel formulation approaches and treatment regimens for mental-health disorders. For more information, visit the company’s website at www.Cybin.com. NOTE TO INVESTORS: The latest news and updates relating to CYBN are available in the company’s newsroom at https://ibn.fm/CYBN

American Cannabis Partners’ Strict Adherence to Jamaican Cultivation Techniques Results in Much Sought-After Flower

  • Jamaican cannabis has benefitted from burgeoning global demand in 2021, with the regulator issuing 42 export licenses
  • American Cannabis Partners has sought to capitalize on growing demand for Jamaican cannabis through a strict adherence to Jamaican cultivation techniques given its close links to the nation
  • US cannabis cultivators are gradually increasing their focus on product differentiation to gain market share within the rapidly growing sector
For Jamaican cannabis cultivators, business is booming. The nation’s industry regulator, the Cannabis Licensing Authority (“CLA”), recently revealed that it had witnessed a dramatic uptick in demand for Jamaican ‘ganja’ on the global market, having issued export licenses to territories as far away as Australia and Germany in recent months, both of which were seeking to import Jamaican cannabis for research and medical purposes. In total, the CLA stated, the regulator had issued 42 export authorizations to 10 entities trading with various regions across the globe thus far this year (https://ibn.fm/9rnFP). “What this tells us is that we have been producing cannabis to the standards required of these other jurisdictions and therefore there is potential for commercial quantities to be exported in the future once markets are opened,” said acting CLA head, Faith Graham. American Cannabis Partners (“ACP”), a multi-state 100% organic cannabis cultivation company headquartered within Northern California’s Emerald Triangle, has sought to capitalize on the global affinity for Jamaican cannabis as well as its close links to the nation through the employment of traditional Jamaican cultivation techniques within their cannabis cultivation, harvesting and curing process. The methods in turn, have resulted in a far superior product for the company, as well as faster growth rates, greater production yields, higher THC levels, and enhanced terpene bouquets (https://ibn.fm/rEUtl). The level of exacting detail and care paid to its plants, as well as its adherence to sustainable Jamaican production practices, have led the company to produce some of the most sought-after flower in the United States, with ACP recently revealing that its new, patent-pending strains marketed under its wholly owned in-house ZUK brand had already seen its entire crop presold for 2021. The U.S. cannabis market has the potential to touch an annual value of $115 billion by 2030 according to Michael Lavery, a senior research analyst at investment bank Piper Sandler, rising from sales of $17.5 billion last year. However, and in a rapidly growing marketplace, Lavery believes that product differentiation will increasingly drive the fortunes and pricing power of the numerous players within the sector (https://ibn.fm/YtMa2). “In this space now, it’s really scarcity that’s driving the value and we see that in every market,” Lavery explained. Cannabis plants habitually produce hundreds of aromatic terpenes, which have been shown to influence both a cannabis plant’s psychoactive properties as well as driving end-consumer demand. American Cannabis Partners has sought to cater to the rapidly evolving consumption tastes of their U.S. audience by way of its meticulous focus on cultivation practices as well as its unique focus on Jamaican techniques, methods which have enabled the company to produce and market a differentiated, niche-market product. Through the adoption of a business model that prizes quality and diversity of its organic end-product above all else, American Cannabis Partners has taken the initial steps towards boosting the company’s profile and competitiveness ahead of a fully legalized U.S. cannabis market. For more information, visit the company’s website at www.ACPFarms.com. NOTE TO INVESTORS: The latest news and updates relating to American Cannabis Partners are available in the company’s newsroom at https://ibn.fm/ACP

FuelPositive Corp (TSX.V: NHHH) (OTCQB: NHHHF) Issues Costing Model and Timeline for Proprietary Green Ammonia Production System

  • FuelPositive’s green ammonia production system is affordable, practical, and about to be available for “real-world” applications in the very near future
  • According to the company’s case study, it costs CA$560 to produce one metric tonne of green anhydrous ammonia in Manitoba using its system, compared to the current average Manitoba delivery cost of CA$900 per metric tonne of grey ammonia
  • Having commenced development of the first prototype in June of 2021, FuelPositive has begun the building of its second and third prototypes
  • It expects to deploy pilot systems throughout 2022
  • FuelPositive expects serial manufacturing to begin in 2023 as batch sizes increase
For FuelPositive (TSX.V: NHHH) (OTCQB: NHHHF), a growth-stage technology company committed to clean energy solutions, 2021 has so far been incredible. Occasioned by the marked progress in the development of its unique modular, scalable system for producing green ammonia (“NH3”), this phenomenal year has steered the company toward the scheduled launch of multiple “real-world” demonstration pilots to showcase its technology throughout 2022, as well as commercialization of its flagship product. In a recent update, FuelPositive released an operational costing model and aggressive timeline to be first to market, both critical to its product’s commercialization (https://ibn.fm/RbXSl). “We are highly efficient, knowledgeable, and experienced in every step we need to take along the way to commercialization. We can move much more quickly than our competitors, and that is one of our great strengths,” commented Ian Clifford, CEO and Board Chairperson of FuelPositive. To come up with a costing model, FuelPositive used a 1,800-acre case study farm in Manitoba, Canada, a province powered by a carbon-free, sustainable electricity grid. As a result, the company established that the cost of producing green ammonia using its system was CA$560 per metric tonne (based on a hydrogen production efficiency rate of 65%), compared to a current average delivery cost of CA$900 per metric tonne of traditionally produced (“grey”) ammonia – a 37.8% decrease. The lower cost, according to a recent Recharge article (https://ibn.fm/ARNZW), is based on the fact that “FuelPositive will combine electrolyzers (which split water molecules into hydrogen and oxygen) with a proprietary reactor that combines nitrogen from the air with H2 using ‘much lower temperatures and much lower pressure’ than Haber-Bosch, resulting in 40% lower costs.” Notably, Haber-Bosch, the production process behind grey ammonia, is energy intensive – needing pressures above 100 bar and temperatures of between 400-500°C. In addition, because the traditional system is powered by fossil fuels, it contributes roughly 1% of the total global carbon emissions annually. If the CO2 emissions from grey hydrogen production (which also relies on fossil fuels), at a rate of 9-18 tons of CO2 for every ton of H2 generated, are taken into account, the quoted emissions from traditional ammonia production are bound to increase even further. In this regard, FuelPositive’s system will substantially reduce overall production and distribution -related emissions. FuelPositive’s calculations are based on Manitoba’s current electricity cost of CAD 0.045/kWh, the largest contributor to the overall production cost of its system. Even so, the total figure does not consider any potential cost reductions as a result of carbon credits or the farmers’ capacity to generate sustainable electricity through on-site solar or wind power generation. The company’s system can produce up to 300 kilograms (500 liters) of green anhydrous ammonia daily, totaling about 100 tonnes per year, an output that is suitable for the 1800-acre model farm. For larger farms, FuelPositive contends that farm owners could simply add sufficient production capacity, aided by the green ammonia production units’ modular, scalable and portable nature. In addition to having a stable, predictable and highly competitive cost per metric tonne, FuelPositive’s green ammonia production system offers independence from the unpredictable fluctuations of grey anhydrous ammonia today. For instance, in just six months, the delivery cost of grey ammonia to Manitoba farmers doubled from C $600 to CA$1,200, resulting in the CA$900 average cost used in the FuelPositive’s costing calculations. Moreover, according to Recharge, FuelPositive’s system will offer farmers and other users additional advantages. For instance, the company is evaluating an ion-exchange membrane (“AEM”) electrolyzers, “which do not require the purified H2O normally required for electrolysis – instead, simple tap water can be used. And that electrolyzer could even be modified to use seawater.” At the same time, green ammonia could provide fuel for the grain-drying process, which is often powered by natural gas or propane – further decreasing CO2 emissions and costs. FuelPositive, which started building its first full-sized prototype system in June this year, immediately after filing for its provisional patent, is already beginning to build the second and third prototypes, applying a batch-style approach to manufacturing. By the beginning of spring next year, the NHHH team expects to be validating the purity of the green ammonia produced by the first prototype system, as well as its operating expenditure (“OPEX”) figures, at which point pre-orders will begin. The company anticipates deploying the first three pilot systems throughout 2022. As batch sizes increase, FuelPositive expects serial manufacturing to begin in 2023. “We are at a point now where we are comfortable with our forecasts. If we have any significant delays or changes, we will communicate that and explain what we are doing about it,” said Nelson Leite, NHHH’s Chief Operating Officer. For more information, visit the company’s website at www.FuelPositive.com. NOTE TO INVESTORS: The latest news and updates relating to NHHHF are available in the company’s newsroom at https://ibn.fm/NHHHF

As Older Population Starts Self-Directed Investing, O&G Company Engages SRAX Inc. (NASDAQ: SRAX) for Targeted Outreach

  • Charles Schwab survey shows 15% of retail investors started during the COVID-19 pandemic in 2020
  • SRAX’s Sequire premier IR communications platform assists public companies understand and communicate with the investment community
  • After following SRAX to understand its expertise, Sino American Oil Company has engaged SRAX
  • More than 250 companies now use Sequire, driving revenue to $8.3 million in Q3 and on the way to the high-end of 2021 guidance
The coronavirus pandemic changed many things in the world, and you can be sure investing is on the list. According to a Charles Schwab survey earlier this year, about 15 percent of today’s retail investor population got started in 2020, a group Schwab has labeled “Generation Investor.” In the survey of about 1,000 people, Schwab also learned that investing respondents are taking a long approach and that it isn’t just younger generations putting their money in the market, a mix that bodes well for communications specialists like SRAX (NASDAQ: SRAX). SRAX is a diversified financial technology, digital marketing and consumer data management company that provides an array of consumer data to its clients valuable to marketing and communications. SRAX’s flagship offering is a premier investor intelligence and communications platform branded Sequire. In September 2020, SRAX also completed the acquisition of LD Micro, arguably the best-known name in data and events serving the small and microcap markets. Schwab’s research discovered a median age of 35 for Generation Investor, comprised of about 11% Baby Boomers, 16% Generation Z, 22% Generations X and the remainder being Millennials. SRAX’s technology unlocks stock buyers’ behaviors and trends for issuers of publicly traded companies. The platform provides insights on shareholders and market makers, investor relations management, shareholder outreach tools, and data-driven marketing. Looking to leverage the SRAX technology to assist with its investor outreach and growth initiatives, oil and gas explorer, Sino American Oil Company (OTCPK: OILY), engaged SRAX this month to better understand its investors and target them in an efficient manner. The partnership will allow Sino American Oil to optimize marketing and communications strategies to reach out to consumers, shareholders, and investors. According to Sino American Oil CEO Kim Halvorson, the company did its due diligence before partnering with SRAX. “We have been following SRAX for some time now, they’re expertise in the Oil and Gas sector and the digital marketing has been impressive,” said Halvorson. Expanding its offerings, SRAX recently launched an IR Website Builder, SMS feature and VIRA, and an IR chatbot. This has translated to a strong improvement in revenue, which rose 219% year-over-year in the third quarter to $8.3 million. With Q4 bookings exceeding $12.5 million so far, SRAX is on track to hit the high end of 2021 guidance, according to CEO Christopher Miglino. For more information, visit the company’s website at www.SRAX.com. NOTE TO INVESTORS: The latest news and updates relating to SRAX are available in the company’s newsroom at http://ibn.fm/SRAX

Tingo, Inc. (IWBB) Seeks to Combine Commercial Success and Rural Community Empowerment

  • Tingo is an Africa-focused agri-fintech company, which seeks to empower rural farming communities through the introduction of innovative farming solutions
  • In addition to driving shareholder returns, the company has also sought to empower societies and produce social upliftment in rural communities in which it is active
  • The company has adopted 5 core sustainable development goals – food security, poverty alleviation, financial inclusion, employment opportunities, & gender equality
By the end of the first quarter of 2021, assets under management held within ESG (Environment, Social, Governance) focused funds around the world had ballooned to $1.984 trillion, driven by a global drive towards increased sustainability and rising social awareness. Soaring investor demand for assets aligning with their social and ethical concerns have turbo-charged inflows towards sustainable investments; in fact, a study found that 89 cents of every dollar invested within active funds in July 2021 was directed towards ESG-focused funds. Tingo (OTCQB: IWBB), a digital service agri-fintech technology company focused on foundation-level agriculture and related financial services in Africa, has made it its mission to both, support the domestic economies of its host countries and support technological and financial inclusion to reduce poverty levels. Thus, and through its unique business model, Tingo hopes to deliver attractive returns to shareholders while simultaneously, investing in the long-term future of the company and its subsidiaries. Tingo Inc aims to be Africa’s leading agri-fintech player, with a multi-pronged strategy which seeks to provide a roadmap through which to address several key areas of social concern within the African continent. As such, the company has sought to adopt five core sustainable development goals as its corporate mission, namely – ensuring food security, driving poverty alleviation, promoting digital financial inclusion, encouraging job creation, and supporting female entrepreneurship and empowerment. A recent study found that nearly 72 percent of Nigerian smallholder farms survived on less than $1.90 per day, with most living well below the poverty line. Moreover, a significant percentage of the farmers were subject to the vagaries of climate change, an increasingly frequent challenge to the success of their individual harvests. Tingo has sought to both, alleviate poverty levels and address food security through the introduction of new and impactful agri-based farming solutions in a bid to create jobs and uplift incomes for millions of rural farmers in select markets. Alongside their goal to boost employment opportunities within rural areas, Tingo has looked to alleviate poverty and promote digital financial inclusion amongst its millions of stake holders through the disruption of legacy micro-finance industries within the African region. The company has sought to provide its users with a range of innovative financial products, alongside an agri-trading platform and credit solutions, designed to helps farmers market their harvests in a more efficient manner and borrow funds at market rates. Farmers will now be able to access DeFi-stable coins and smart contracts, thereby providing agri-communities access to credit-market driven digital finance solutions to held make them more competitive. Through the company’s proprietary and proven digital technology platforms, Tingo will seek to provide low-cost and dignified mobile transaction services using a dedicated mobile application, thereby lifting a key business barrier to what has historically been a largely underbanked populace. A key tenet underpinning Tingo’s business model has been the company’s steadfast commitment to gender equality. Tingo has looked to encourage female entrepreneurship within Africa’s rural communities through the introduction of training schemes designed to encourage women to operate both, farming and collection businesses. The success of the scheme is best illustrated through Tingo’s burgeoning agent network, which currently consists of approximately 15,000 members – the overwhelming majority of whom are women (https://ibn.fm/qj4GM). In a global economy which is increasingly seeing growing socio-economic differences and competitive pressures, Tingo Inc has sought to create a unique business model which seeks to build out the company as one of Africa’s leading agri-fintech providers while simultaneously, contributing to bettering the lives of millions with Africa’s rural communities. For more information, visit the company’s website at www.TingoGroup.com. NOTE TO INVESTORS: The latest news and updates relating to IWBB are available in the company’s newsroom at https://ibn.fm/IWBB

From Our Blog

Powermax Minerals Inc. (CSE: PMAX) (OTCQB: PWMXF) Set to Capitalize on North American Push to Secure Rare Earth Supply Chains

December 24, 2025

Disseminated on behalf of  Powermax Minerals Inc. (CSE: PMAX) (OTCQB: PWMXF) and may include paid advertising. A wave of recent investment announcements across the United States is underscoring how rare earth elements have moved from niche commodities to strategic priorities. From refining facilities in Louisiana to magnet recycling hubs in Texas, governments and companies are […]

Rotate your device 90° to view site.